Pharmacologic Treatment of Type 2 Diabetes: Injectable Medications

Annals of Pharmacotherapy

Volumn 49, Issue 6, 2015, Pages 700-714

  Tran, Linda ^a   Zielinski, Angela ^a   Roach, Arpi H ^a   Jende, Jennifer A ^a   Householder, Ann Marie ^a   Cole, Emily E ^a   Atway, Shuruq A ^a   Amornyard, Melinda ^a   Accursi, Mallory L ^a   Shieh, Suzanna W ^a   Thompson, Erin E ^a  

^a Chalmers P Wylie VA Ambulatory Care Center   (United States)

Author keywords

biguanide; bile acid sequestrant; biphasic insulin; diabetes medications; diabetes mellitus; dipeptidyl peptidase 4 inhibitor; dopamine receptor agonist; DPP4 I; GLP 1 agonist; glucagon like peptide 1 agonist; insulin; intermediate acting insulin; investigational agent; long acting insulin; meglitinide; pramlintide; prandial insulin; rapid acting insulin; review; SGLT2 I; short acting insulin; sodium glucose cotransporter 2 inhibitor; sulfonylurea; thiazolidinedione; type 2 diabetes; TZD; U 500 regular insulin; ultra rapid acting inhaled insulin; glucosidase inhibitor

Indexed keywords

BIPHASIC INSULIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN DEGLUDEC; INSULIN GLARGINE; LONG ACTING INSULIN; NEW DRUG; PIG INSULIN; PRAMLINTIDE; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; INSULIN; METFORMIN;

DATA EXTRACTION; DIABETIC PATIENT; DRUG APPROVAL; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; INVESTIGATIVE PROCEDURES; MEDICAL INFORMATION; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN;

EID: 84930585595     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015573010     Document Type: Review

References (185)

1. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).Lancet. 1998;352:837-853
2. Patel A,MacMahon S,Chalmers J, et al.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med. 2008;358:2560-2572
3. Ismail-Beigi F,Craven T,Banerji MA, et al.Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial.Lancet. 2010;376:419-430
4. Duckworth W,Abraira C,Mortiz W, et al.Glucose control and vascular complications in veterans with type 2 diabetes.N Engl J Med. 2009;360:129-139
5. FDA-Approved Diabetes Medicines. http://www.fda.gov/forpatients/illness/diabetes/ucm408682.htm. Accessed October 23, 2014.
6. FDA News Release: FDA approves Afrezza to treat diabetes. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403122.htm. Accessed July 13, 2014.
7. FDA News Release: FDA approves Tanzeum to treat type 2 diabetes. http://www.fda.gov/newsevents/newsroom/pressanno-uncements/ucm393289.htm. Accessed July 20, 2014.
8. Indianapolis, IN: Eli-Lilly, Bridgewater; 2014:
9. Wilmington, DE: AstraZeneca; 2014:
10. Hollander PA,Levy P,Fineman MS, et al.Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.Diabetes Care. 2003;26:784-790
11. Hollander P,Ratner R,Fineman M, et al.Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.Diabetes Obes Metab. 2003;5:408-414
12. Karl D,Philis-Tsimikas A,Darsow T, et al.Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.Diabetes Technol Ther. 2007;9:191-199
13. Riddle M,Frias J,Zhang B, et al.Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.Diabetes Care. 2007;30:2794-2799
14. Pencek R,Roddy T,Peters Y, et al.Safety of pramlintide added to mealtime insulin in patients with type 1 or type 2 diabetes: a large observational study.Diabetes Obes Metab. 2010;12:548-551
15. Holst JJ.The physiology of glucagon-like peptide 1.Physiol Rev. 2007;87:1409-1439
16. Princeton, NJ: Bristol-Myers Squib Co; 2013:
17. Plainsboro, NJ: NovoNordisk; 2013:
18. Princeton, NJ: Bristol-Myers Squib Co; 2013:
19. Wilmington, DE: GlaxoSmithKline LLC; 2014:
20. Barrington P,Chien CY,Showalter HDH,Cui S,Tibaldi F.A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide 1-analogue, in patients with type 2 diabetes.Diabetes Obes Metab. 2011;13:426-433
21. Wysham C,Blevins T,Arakaki R, et al.Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).Diabetes Care. 2014;37:2159-2167
22. Umpierrez G,Tofé Povedano S,Pérez Manghi F,Shurzinske L,Pechtner V.Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).Diabetes Care. 2014;37:2168-2176
23. Nauck M,Weinstock RS,Umpierrez GE,Guerci B,Skrivanek Z,Milicevic Z.Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).Diabetes Care. 2014;37:2149-2158
24. Moretto TJ,Milton DR,Ridge TD, et al.Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.Clin Ther. 2008;30:1448-1460
25. Garber A,Henry R,Ratner R, et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.Lancet. 2009;373:473-481
26. Russell-Jones D,Cuddihy RM,Hanfeld M, et al.Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4).Diabetes Care. 2012;35:252-258
27. Reinhardt R,Nauck MA,Stewart M, et al.HARMONY 2 results at week 52 primary endpoint: once-weekly albiglutide monotherapy for patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.Diabetologia. 2013;56:S360
28. DeFronzo RA,Ratner RE,Han J,Kim DD,Fineman MS,Baron AD.Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.Diabetes Care. 2005;28:1092-1100
29. Buse JB,Henry RR,Han J,Kim DD,Fineman MS,Baron AD.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.Diabetes Care. 2004;27:2628-2635
30. Kendall DM,Riddle MC,Rosenstock J, et al.Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.Diabetes Care. 2005;28:1083-1091
31. Zinman B,Hoogwerd BJ,Garcia SD, et al.The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes.Ann Intern Med. 2007;146:477-485
32. Heine RJ,Van Gaal LF,Johns D,Mihm MJ,Widel MH,Brodows RG.Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes.Ann Intern Med. 2005;143:559-569
33. Barnett AH,Burger J,Johns D, et al.Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.Clin Ther. 2007;29:2333-2348
34. Marre M,Shaw J,Brandle M, et al.Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with added rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU).Diabet Med. 2009;26:268-278
35. Nauck M,Frid A,Hermansen K, et al.Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes.Diabetes Care. 2009;32:84-90
36. Russell-Jones D,Vaag A,Schmitz O, et al.Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.Diabetologia. 2009;52:2046-2055
37. Zinman B,Gerich J,Buse JB, et al.Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD).Diabetes Care. 2009;32:1224-1230
38. Buse JB,Rosenstock J,Sesti G, et al.Liraglutide once weekly versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).Lancet. 2009;374:39-47
39. Pratley RE,Nauck M,Bailey T, et al.Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.Lancet. 2010;375:1447-1456
40. Buse JB,Nauck M,Forst T, et al.Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.Lancet. 2013;381:117-124
41. Drucker DJ,Buse JB,Taylor K, et al.Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.Lancet. 2008;372:1240-1250
42. Bergenstal RM,Wysham C,MacConell L, et al.Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.Lancet. 2010;376:431-439
43. Diamant M,Van Gaal L,Stranks S, et al.Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.Lancet. 2010;375:223-243
44. Blevins T,Pullman J,Malloy J, et al.DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.J Clin Endocrinol Metab. 2011;96:1301-1310
45. Kim D,MacConell L,Zhuang D, et al.Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.Diabetes Care. 2007;30:1487-1493
46. Ahren B,Johnson S,Stewart M, et al.HARMONY 3: 104-week randomized, double blind, placebo-and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.Diabetes Care. 2014;37:2141-2148
47. Pratley R,Stewart M,Cirkel D, et al.HARMONY 4: 52-week efficacy of albiglutide vs insulin glargine in patients with type 2 diabetes mellitus.Diabetologia. 2013;56:S360
48. Stewart M,Home P,Yang F,Perry C,Carr MC.52-week efficacy of albiglutide vs placebo and vs pioglitazone in triple therapy (background metformin and glimepiride) in patients with type 2 diabetes: HARMONY 5 study.Diabetologia. 2013;56:S361
49. Pratley RE,Nauck MA,Barnett AH, et al.Once-weekly albiglutide verses once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open label, multicentre, non-inferiority phase 3 study.Lancet Diabetes Endocrinol. 2014;2:289-297
50. Woodward H,Anderson A.Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.Patient Prefer Adherence. 2014;8:789-803
51. Leiter L,Carr M,Steward M, et al.Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.Diabetes Care. 2014;37:2723-2730
52. Giorgino F,Benroubi M,Sun JH,Zimmermann AG,Pechtner V.Efficacy and safety of once-weekly dulaglutide vs. insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2).Paper presented at: 74th Scientific Session American Diabetes Association; San Francisco, CA;.
53. Rosenstock J,Fonseca V,Gross J, et al.Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice daily prandial insulin lispro.Diabetes Care. 2014;37:2317-2325
54. Nauck MA,Duran S,Kim D, et al.A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.Diabetologia. 2007;50:259-267
55. Buse JB,Drucker DJ,Taylor KL, et al.DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.Diabetes Care. 2010;33:1255-1261
56. Dungan KM,Povedano ST,Forst T, et al.Once-weekly dulaglutide versus once-daily liraglutide in metformin- treated patients with type 2 diabetes (AWARD-6): a randomized, open-label, phase 3, non-inferiority trial.Lancet. 2014;384:1349-1357
57. Rosenstock J,Reusch J,Bush M,Yang F,Stewart M.Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes.Diabetes Care. 2009;32:1880-1886
58. Nauck M,Frid A,Hermansen K, et al.Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.Diabetes Obes Metab. 2013;15:204-212
59. Klonoff DC,Buse JB,Nielsen LL, et al.Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.Curr Med Res Opin. 2008;24:275-286
60. Buse JB,Sesti G,Schmidt WE, et al.Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.Diabetes Care. 2010;33:1300-1303
61. Taylor K,Gurney K,Han J,Pencek R,Walsh B,Trautmann M.Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.BMC Endocr Disord. 2011;11:9
62. MacConell L,Pencek R,Li Y,Maggs D,Porter L.Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.Diabetes Metab Syndr Obes. 2013;6:31-41
63. Diamant M,Van Gaal L,Stranks S, et al.Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.Diabetes Care. 2012;35:683-689
64. Elashoff M,Matveyenko AV,Gier B,Elashoff R,Butler PC.Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.Gastroenterology. 2011;141:150-156
65. Parola T. Victoza (liraglutide injections): human relevance of rodent thyroid C-cell tumors. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm151129.pdf. Accessed March 15, 2014.
66. FDA Drug Safety Communication. FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes. http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm. Accessed March 16, 2014.
67. Girman CJ,Kou TD,Cai B, et al.Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes.Diabetes Obes Metab. 2010;12:766-771
68. European Medicines Agency. Investigation into GLP-1 based diabetes therapies concluded. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1. Accessed August 18, 2014.
69. Egan A,Blind E,Dunder K, et al.Pancreatic safety of incretin-based drugs: FDA and EMA assessment.N Engl J Med. 2014;370:794-797
70. Stranges P,Khanderia U.Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies.Ther Adv Drug Saf. 2014;3:185-201
71. Monami M,Cremasco F,Lamanna C, et al.Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.Exp Diabetes Res. 2011;2011:215764
72. Seufert J,Gallwitz B.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Diabetes Obes Metab. 2014;16:673-688
73. Monami M,Dicembrini I,Nardini C,Fiordelli I,Mannucci E.Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.Diabetes Obes Metab. 2014;16:38-47
74. Marso SP,Poulter NR,Nissen SE, et al.Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.Am Heart J. 2013;166:823-830
75. Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://clinicaltrials.gov/show/NCT01144338. Accessed March 11, 2014.
76. Bridgewater, NJ: Sanofi-Aventis; 2013:
77. Bagsvaerd, Denmark: Novo Nordisk; 2013:
78. Indianapolis, IN: Lilly USA; 2013:
79. Indianapolis, IN: Lilly USA; 2013:
80. Bagsvaerd, Denmark: Novo Nordisk; 2013:
81. Indianapolis, IN: Lilly USA; 2013:
82. Bagsvaerd, Denmark: Novo Nordisk; 2013:
83. Plainsboro, NJ: Novo Nordisk; 2014:
84. Indianapolis, IN: Eli Lilly & Company; 2013:
85. Bridgewater, NJ: Sanofi-Aventis; 2014:
86. Plank J,Bodenlenz M,Sinner F, et al.A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.Diabetes Care. 2005;28:1107-1112
87. Hollander P,Cooper J,Bregnhøi J,Pedersen CB.A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.Clin Ther. 2008;30:1976-1987
88. Raskin P,Gylvin T,Weng W,Chaykin L.Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.Diabetes Metab Res Rev. 2009;25:542-548
89. Rosenstock J,Davies M,Home PD,Larsen J,Koenen C,Schernthaner G.A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.Diabetologia. 2008;51:408-416
90. Swinnen SG,Dain MP,Aronson R, et al.A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.Diabetes Care. 2010;33:1176-1178
91. Swinnen SG,Simon AC,Holleman F,Howkstra JB,Devries JH.Insulin detemir versus insulin glargine for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2011; (6): CD006383
92. Fakhoury W,Lockhart I,Kotchie RW,Aggren M,LeRun C.Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.Pharmacology. 2008;82:156-163
93. Mäkimattila S,Nikkilä K,Yki-Järvinen H.Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus.Diabetologia. 1999;42:406-412
94. Sallé A,Ryan M,Guilloteau G,Bouhanick B,Berrut G,Ritz P.“Glucose control-related” and “non-glucose control-related” effects of insulin weight gain in newly insulin-treated type 2 diabetic patients.Br J Nutr. 2005;96:931-937
95. Zib I,Raskin P.Novel insulin analogues and its mitogenic potential.Diabetes Obes Metab. 2006;8:611-620
96. Hemkens LG,Grouven U,Bender R, et al.Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.Diabetologia. 2009;52:1732-1744
97. Jonasson JM,Ljung R,Talbäck M,Haglund B,Gudbjörnsdòttir S,Steineck G.Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.Diabetologia. 2009;52:1745-1754
98. Currie CJ,Poole CD,Gale EA.The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.Diabetologia. 2009;52:1766-1777
99. Fagot JP,Blotière PO,Ricordeau P,Weill A,Alla F,Allemand H.Does insulin glargine increase the risk of cancer compared with other basal insulins? A French nationwide cohort study based on national administrative databases.Diabetes Care. 2013;36:294-301
100. Nathan DM,Buse JB,Davidson MB, et al.Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the study of Diabetes.Diabetes Care. 2009;32:193-203
101. Food and Drug Administration. FDA drug safety communication: update to ongoing safety review of Lantus (insulin glargine) and possible risk of cancer. http://www.fda.gov/Drugs/DrugSafety/ucm239376.htm. Accessed February 24, 2014.
102. European Medicines Agency. Outcomes of review of new safety data on insulin glargine. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143823.pdf. Accessed March 16, 2014.
103. Riddle MC,Rosenstock J,Gerich J.The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.Diabetes Care. 2003;26:3080-3086
104. Hamaty M.Insulin treatment for type 2 diabetes: when to start, which to use.Cleve Clin J Med. 2011;78:332-342
105. Petznick A.Insulin management of type 2 diabetes mellitus.Am Fam Physician. 2011;84:183-190
106. Hamann A,Mattheal S,Rosak C,Silvestre L.A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.Diabetes Care. 2003;26:1738-1744
107. Massi Benedetti M,Humburg E,Dressler A,Ziemen M.A one-year, randomized, multicenter trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.Horm Metab Res. 2003;35:189-196
108. Yki-Järvinen H,Kauppinen-Mäkelin R,Tiikkainen M, et al.Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.Diabetologia. 2006;49:442-451
109. Fritsche A,Schweitzer MA,Häring HU.Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial.Ann Intern Med. 2003;138:952-959
110. Rosenstock J,Schwartz SL,Clark CM,Park GD,Donley DW,Edwards MB.Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOW 901) and NPH insulin.Diabetes Care. 2001;24:631-636
111. Eliaschewitz FG,Calvo C,Valbuena H, et al.Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.Arch Med Res. 2006;37:495-501
112. Home PD,Bolli GB,Mathieu C, et al.Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.Diabetes Obes Metab. 2014;:
113. Meneghini L,Koenen C,Weng W,Selam JL.The use of a simplified self-titration dosing guidelines (303 algorithm) for insulin detemir in patients with type 2 diabetes: results of the randomized, controlled PREDICTIVE 303 study.Diabetes Obes Metab. 2007;9:902-913
114. Gerstein HC,Yale JF,Harris SB,Issa M,Stewart JA,Dempsey E.A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycemia Treatment) Study.Diabet Med. 2006;23:736-742
115. Davies M,Storms F,Shutler S,Bianchi-Biscay M,Gomis R.Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine.Diabetes Care. 2005;28:1282-1288
116. Yki-Järvinen H,Juurinen L,Alvarsson M, et al.Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups.Diabetes Care. 2007;30:1364-1369
117. Hermansen K,Davies M,Derezinski T,Martinez Raven G,Clauson P,Home P.A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes.Diabetes Care. 2006;29:1269-1274
118. Janka HU,Pleme G,Riddle MC,Kliebe-Frisch C,Schweitzer MA,Yki-Järvinen H.Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.Diabetes Care. 2005;28:254-259
119. Kennedy L,Herman WH,Strange P,Harries A.Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HgA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial.Diabetes Care. 2006;29:1-8
120. Holman RR,Thorne KI,Farmer AJ, et al.Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.N Engl J Med. 2007;357:1716-1730
121. Holmann RR,Farmer AJ,Davies MJ, et al.Three-year efficacy of complex insulin regimens in type 2 diabetes.N Engl J Med. 2009;361:1736-1747
122. Bergenstal RM,Johnson M,Powers MA, et al.Adjustment to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin gluisine.Diabetes Care. 2008;31:1305-1310
123. Kawamori R,Eliaschewitz FG,Takayama H,Hayashida CY.Efficacy of insulin glargine and glimiperide in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.Diabetes Res Clin Pract. 2008;79:97-102
124. Blonde L,Merilainen M,Karwe V,Raskin P.Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets. The TITRATE study.Diabetes Obes Metab. 2009;11:623-631
125. Liebl A,Prager R,Binz K, et al.Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER study: a randomized controlled trial.Diabetes Obes Metab. 2009;11:45-52
126. Arnolds S,Dellweg S,Clair J, et al.Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.Diabetes Care. 2010;33:1509-1515
127. Strange P.Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes.J Diabetes Sci Technol. 2007;1:540-548
128. Rosenstock J,Fonseca V,Schinzel S,Dain MP,Mullins P,Riddle M.Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial.J Diabetes Complications. 2014;28:742-749
129. Siegmund T,Weber S,Blankenfeld H,Oeffner A,Schumm-Draeger PM.Comparison of insulin glargine versus NPH insulin in people with type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.Exp Clin Endocrinol Diabetes. 2007;115:349-353
130. Haak T,Tiengo A,Draeger E,Suntum M,Waldhusl W.Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.Diabetes Obes Metab. 2005;7:56-64
131. Raslová K,Bogoev M,Raz I,Leth G,Gall MA,Hâncu N.Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.Diabetes Res Clin Pract. 2004;66:193-201
132. Singh SR,Ahmad F,Lal A,Yu C,Bai Z,Bennett H.Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.CMAJ. 2009;180:385-397
133. Waugh N,Cummins E,Royle P, et al.Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Health Technol Assess. 2010;14:1-248
134. Horvath K,Jeitler K,Berghold A, et al.Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2007; (2): CD005613
135. De La Pena A,Riddle M,Morrow LA, et al.Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.Diabetes Care. 2011;34:2496-2501
136. Jørgensen KH,Hansen AK,Buschard K.Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs.Diabetes Res Clin Pract. 2000;50:161-167
137. Lane WS,Cochran EK,Jackson JA, et al.High-dose insulin therapy: is it time for U-500 insulin?.Endocr Pract. 2009;15:71-79
138. Cochran E,Gorden P.Use of U-500 insulin in the treatment of severe insulin resistance.Insulin. 2008;3:211-218
139. Cochran E,Musso C,Gorden P.The use of U-500 in patients with extreme insulin resistance.Diabetes Care. 2005;28:1240-1244
140. Davidson MB,Navar MD,Echeverry D,Durna P.U-500 regular insulin clinical experience and pharmacokinetics in obese, severely insulin resistant type 2 diabetic patients.Diabetes Care. 2010;33:281-283
141. Ballani P,Tran MT,Navar MD,Davidson MB.Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients.Diabetes Care. 2006;2:2504-2505
142. Neal JM.Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy.Endocr Pract. 2005;11:305-307
143. Dailey AM,Williams S,Taneja D,Tannock LR.Clinical efficacy and patient satisfaction with U-500 insulin use.Diabetes Res Clin Pract. 2010;88:259-264
144. Quinn SL,Lansang MC,Mina D.Safety and effectiveness of U-500 insulin therapy in patients with insulin-resistant type 2 diabetes mellitus.Pharmacotherapy. 2011;31:695-702
145. Nayyar V,Jarvia J,Lawrence I, et al.Long-term follow up of patients on U-500 insulin: a case series.Pract Diabetes Int. 2010;27:194-197
146. Wafa WS,Khan MI.Use of U-500 regular insulin in type 2 diabetes.Diabetes Care. 2006;29:2175-2176
147. Reutrakul A,Wroblewski K,Brown RL.Clinical use of U-500 regular insulin: review and meta-analysis.J Diabetes Sci Technol. 2012;6:412-420
148. Lane WS,Weinrib SL,Rappaport JM,Hale CB,Farmer LK,Lane RS.The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes.Endocr Pract. 2013;19:196-201
149. Andres J,Clements JN.A practical guide to concentrated insulin for pharmacists.J Pharm Pract. 2014;:
150. Institute for Safe Medication Practices. Extra caution needed with U-500 insulin: ISMP medication safety alert!http://www.ismp.org/newsletters/acutecare/articles/19970129.asp. Accessed October 9, 2014.
151. Garg R,Johnston V,McNally PG,Davies MJ,Lawrence IG.U-500 insulin: why, when and how to use in clinical practice.Diabetes Metab Res Rev. 2007;23:265-268
152. Dailey AM,Tannock LR.Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.Curr Diab Rep. 2011;11:77-82
153. Eby EL,Wang P,Curtis BH, et al.Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.J Med Econ. 2013;16:529-538
154. Eby EL,Zagar AJ,Wang P, et al.Healthcare costs and adherence associated with human regular U-500 versus high-dose U-100 insulin in patients with diabetes.Endocr Pract. 2014;20:663-670
155. Bretzel RG,Eckhard M,Landgraf W,Owens DR,Linn T.Initiating insulin therapy in type 2 diabetic patients failing on oral hypoglycemic agents.Diabetes Care. 2009;32:S260-S265
156. Abrahamson MJ,Peters A.Intensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapy.Ann Med. 2012;44:836-846
157. Owens DR,van Schalkwyk C,Smith P, et al.Algorithm for introduction of rapid-acting insulin analogues in patients with type 2 diabetes on basal insulin therapy.Pract Diab Int. 2009;26:70-77
158. Association of Clinical Endocrinologists medical guidelines for the management of diabetes: AACE Comprehensive Diabetes Management Algorithm.Endocr Pract. 2013;19:333
159. Dewitt DE,Dugdale D.Using new insulin strategies in the outpatient treatment of diabetes.JAMA. 2003;17:2266-2269
160. Morello CM.Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus.Int J Gen Med. 2011;4:827-835
161. Mudaliar SR,Lindberg FA,Joyce M, et al.Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular insulin in healthy nondiabetic subjects.Diabetes Care. 1999;22:1501-1506
162. Perriello G,Pampanelli S,Porcellati F, et al.Insulin aspart improves meal time glycaemic control in patients with type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.Diabet Med. 2005;22:606-611
163. Davey P,Grainger D,MacMillan J,Rajan N,Aristides M,Gliksman M.Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.Clin Ther. 1997;19:656-674
164. Ross SA,Zinman B,Campos RV,Strack T.A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.Clin Invest Med. 2001;24:292-298
165. Dailey G,Rosenstock J,Moses R,Ways K.Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.Diabetes Care. 2004;27:2363-2368
166. Plank J,Siebenhofer A,Berhold A, et al.Short acting insulin analogues versus regular insulin in patient with diabetes mellitus.Cochrane Database Syst Rev. 2006; (2): CD003287
167. Rave K,Potocka E,Heinemann L, et al.Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.Diabetes Obes Metab. 2009;11:715-720
168. Rosenstock J,Lorber DL,Gnudi L, et al.Prandial inhaled insulin plus basal insulin glargine versus twice biaspart insulin for type 2 diabetes: a multicentre randomised trial.Lancet. 2010;375:2244-2253
169. Raskin P,Heller S,Honka M, et al.Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial.Diabetes Obes Metab. 2012;14:163-173
170. Danbury, CT: MannKind Corporation; 2014:
171. Owens DR.Stepwise intensification of insulin therapy in type 2 diabetes management: exploring the concept of the basal-plus approach in clinical practice.Diabet Med. 2013;30:276-288
172. Ampudia-Blasco FJ,Rossetti P,Ascaso JF.Basal plus basal-bolus approach in type 2 diabetes.Diabetes Technol Ther. 2011;13:S75-S83
173. Plainsboro, NJ: Novo Nordisk; 2010:
174. Indianapolis, IN: Eli Lilly & Company; 2010:
175. Indianapolis, IN: Eli Lilly & Company; 2013:
176. Plainsboro, NJ: Novo Nordisk; 2013:
177. Giugliano D,Chiodini P,Maiorino MI,Ceriello A,Bellastella G,Esposito K.Efficacy of insulin analogs in achieving the hemoglobin A1c target < 7% in type 2 diabetes.Diabetes Care. 2011;34:510-517
178. Heise T,Nosek L,Bottcher SG,Hastrup H,Haahr H.Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.Diabetes Obes Metab. 2012;14:944-950
179. Rodbard HW,Cariou B,Zinman B, et al.Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized treat to target trial.Diabet Med. 2013;11:1298-1304
180. Novo Nordisk. Novo Nordisk receives complete response letter in the US for Tresiba® and Ryzodeg®. http://www.novonordisk.com/include/asp/exe_news_attachment.asp?sAttachmentGUID=83700060-0ce3-4577-a35a-f3e57801637d. Accessed March 13, 2014.
181. Jax T,Heise T,Dahmen R, et al.New insulin glargine formulation has a flat and prolonged steady state profile in subjects with type 1 diabetes.Diabetologia. 2013;56:A1029
182. Riddle MC,Bolli GB,Ziemen M,Muehlen-Bartmer I,Bizet F,Home PD.New insulin glargine formulation: glucose control and hypoglycaemia in people with type 2 diabetes using basal and mealtime insulin (EDITION 1).Diabetologia. 2013;56:A220
183. Ritzel R,Rouseel R,Bolli GB,Vinet L,Yki-Jarvinen H.New insulin glargine 300 U/ml: glycemic control and hypoglycemia in a meta-analysis of phase 3a EDITION clinical trials in people with T2DM.Paper presented at: 74th Scientific Session, American Diabetes Association; San Fransisco, CA;.
184. Bridgewater, NJ: Sanofi-Aventis; 2015:
185. Inzucchi SE,Bergenstal RM,Buse JB, et al.Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2015;38:140-149